HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Waves Stop Sign At Kratom Product Launch After Failed NDI Notification

This article was originally published in The Rose Sheet

Executive Summary

FDA published an untitled letter the same day it was submitted stating that Industrial Chemicals' website includes statements on kratom's safety as a dietary ingredient and its pending launch of product sales even though the agency in December said an NDI notification the firm submitted in September did not establish safety for the use of mitragynine, an extract from dried kratom leaves, in a supplement branded Mitrasafe.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel